Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David E. Avigan, M.D.

Co-Author

This page shows the publications co-authored by David Avigan and Surender Kharbanda.
Connection Strength

0.207
  1. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. 2016 Jun 28; 7(26):38974-38987.
    View in: PubMed
    Score: 0.042
  2. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood. 2014 Jan 30; 123(5):734-42.
    View in: PubMed
    Score: 0.035
  3. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood. 2011 May 05; 117(18):4863-70.
    View in: PubMed
    Score: 0.029
  4. Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. Cancer Biol Ther. 2010 Sep 01; 10(5):483-91.
    View in: PubMed
    Score: 0.028
  5. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharmacol. 2010 Aug; 78(2):166-74.
    View in: PubMed
    Score: 0.027
  6. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009 Jun 15; 69(12):5133-41.
    View in: PubMed
    Score: 0.026
  7. A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells. Cancer Chemother Pharmacol. 2007 Feb; 59(3):329-35.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.